Why emerging biotech companies must rethink lab infrastructure and how flexible, shared labs can reduce costs, preserve runway, and help companies scale.

Emerging biotech companies can optimize laboratory space through flexible layouts, advanced equipment, scalable infrastructure, and collaboration that improve efficiency and accelerate scientific research.

Labshares and Byte51 help biotech startups navigate fundraising with investor data, competitive insights, market trends, and access to a funding intelligence platform powered by more than $650 billion in science and VC data.